07:35 AM EDT, 08/27/2024 (MT Newswires) -- (Updates with the pricing and discount details in the third paragraph.)

Eli Lilly ( LLY ) said Tuesday that single-dose vials of its Zepbound treatment for obesity in adults are now available for self-paying patients with on-label prescriptions, expanding access to the product.

The vials come in 2.5-milligram and 5 mg doses and are available through a new self-pay pharmacy division of the company's LillyDirect, according to the company.

Eli Lilly ( LLY ) priced a four-week supply of the 2.5 mg Zepbound single-dose vial at $399 and a four-week supply of the 5 mg dose at $549, "less than half the list price of other incretin medicines for obesity," the company said.

Price: 944.00, Change: -6.53, Percent Change: -0.69